RT Journal Article
SR Electronic
T1 Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 878
OP 883
DO 10.1136/jclinpath-2015-203265
VO 69
IS 10
A1 Iravani, Omid
A1 Yip, George Wai-Cheong
A1 Thike, Aye Aye
A1 Chua, Pei Jou
A1 Jane Scully, Olivia
A1 Tan, Puay-Hoon
A1 Bay, Boon-Huat
YR 2016
UL http://jcp.bmj.com/content/69/10/878.abstract
AB Aims Altered expression of the Claudin (CLDN) superfamily of tight junction proteins has been reported in breast cancer. The aim of this study was to examine the immunohistochemical expression of CLDN 12 and its prognostic significance in breast cancer tissues.Methods Immunohistochemical expression of CLDN 12 was performed on tissue microarrays consisting of 232 cases of breast carcinoma and correlated with clinicopathological features as well as survival of the patients with breast cancer.Results For the estrogen receptor (ER)-negative subgroup of patients with breast cancer, CLDN 12 expression was shown to be an independent predictor of poor overall survival (HR=2.345; p=0.020) and disease-free survival (HR=2.177; p=0.026) but not for the ER-positive tumours.Conclusions The findings suggest that CLDN 12 expression could be clinically useful for predicting the survival of the ER-negative subgroup of patients with breast cancer.